![PRD_000275 PRD_000275](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000275.svg) | PRD_000275 | Name: | Ac-DADE-F(2)Pmp-L-NH(2) | Formula: | C32 H46 F2 N7 O15 P | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000276 PRD_000276](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000276.svg) | PRD_000276 | Name: | Thrombostatin FM inhibitor [rOicPaF(p-Me)] | Formula: | C33 H52 N9 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000277 PRD_000277](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000277.svg) | PRD_000277 | Name: | N-[(benzyloxy)carbonyl]-L-alpha-aspartyl-L-alpha-glutamyl-N-[(1S)-1-(carboxymethyl)-3-chloro-2-oxopropyl]-L-valinamide | Formula: | C27 H35 Cl N4 O12 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000278 PRD_000278](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000278.svg) | PRD_000278 | Name: | DECANOYL-ARG-VAL-LYS-ARG-CHLOROMETHYLKETONE | Formula: | C34 H71 Cl N11 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000279 PRD_000279](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0FG.svg) | PRD_000279 | Name: | D-leucyl-N-(4-fluorobenzyl)-L-phenylalaninamide | Formula: | C22 H28 F N3 O2 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000280 PRD_000280](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000280.svg) | PRD_000280 | Name: | HIV ENTRY INHIBITOR PIE1 | Formula: | C80 H118 N22 O22 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000281 PRD_000281](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000281.svg) | PRD_000281 | Name: | HIV ENTRY INHIBITOR PIE7 | Formula: | C81 H110 N20 O22 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000282 PRD_000282](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000282.svg) | PRD_000282 | Name: | N-acetyl-L-alpha-aspartyl-L-asparaginyl-N-[(1R)-2-carboxy-1-formylethyl]-L-leucinamide | Formula: | C20 H33 N5 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000283 PRD_000283](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0FP.svg) | PRD_000283 | Name: | N-(6-aminohexanoyl)-3-methyl-L-valyl-3-methyl-L-valyl-N~1~-[(2S,3S)-3-hydroxy-4-oxo-4-{[(1R)-1-phenylpropyl]amino}butan-2-yl]-N~4~,N~4~-dimethyl-L-aspartamide | Formula: | C37 H63 N7 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000284 PRD_000284](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000284.svg) | PRD_000284 | Name: | AC-DQMD-CHO | Formula: | C20 H33 N5 O10 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000285 PRD_000285](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000285.svg) | PRD_000285 | Name: | L-tryptophyl-L-tyrosyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-threoninamide | Formula: | C31 H44 Cl N8 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000286 PRD_000286](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000286.svg) | PRD_000286 | Name: | D-valyl-N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-L-leucinamide | Formula: | C18 H36 Cl N4 O3 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000287 PRD_000287](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0GE.svg) | PRD_000287 | Name: | N-{[5-(dimethylamino)naphthalen-1-yl]sulfonyl}-L-alpha-glutamyl-N-[(2S,3S)-6-carbamimidamido-1-chloro-2-hydroxyhexan-3-yl]glycinamide | Formula: | C26 H38 Cl N7 O7 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000288 PRD_000288](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0GJ.svg) | PRD_000288 | Name: | L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide | Formula: | C14 H28 Cl N6 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000289 PRD_000289](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000289.svg) | PRD_000289 | Name: | BETA-SECRETASE INHIBITOR OM00-3 | Formula: | C44 H69 N7 O15 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000290 PRD_000290](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000290.svg) | PRD_000290 | Name: | BETA-SECRETASE INHIBITOR OM99-2 | Formula: | C41 H64 N8 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000293 PRD_000293](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000293.svg) | PRD_000293 | Name: | INHIBITOR AC-ESMD-CHO | Formula: | C19 H32 N4 O10 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000295 PRD_000295](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000295.svg) | PRD_000295 | Name: | GLU-VAL-DEHYDROXYMETHYLASPARTIC ACID INHIBITOR | Formula: | C23 H30 Cl N3 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000296 PRD_000296](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0GQ.svg) | PRD_000296 | Name: | 4-amino-N-{(1R,8R,9R,13R)-16-(4-amino-2-methylpyrimidin-5-yl)-1-benzyl-8-(cyclohexylmethyl)-9-hydroxy-13-[(1S)-1-methylpropyl]-2,6,11,14-tetraoxo-3,7,12,15-tetraazahexadec-1-yl}piperidine-1-carboxamide | Formula: | C41 H64 N10 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000297 PRD_000297](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0GR.svg) | PRD_000297 | Name: | N-(furan-2-ylcarbonyl)-L-leucyl-L-tryptophan | Formula: | C22 H25 N3 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000298 PRD_000298](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000298.svg) | PRD_000298 | Name: | N-[(2R)-3-phenyl-2-{[L-prolyl-L-phenylalanyl-3-(1H-imidazol-3-ium-4-yl)-L-alanyl]amino}propyl]-L-phenylalanyl-L-valyltyrosine | Formula: | C58 H72 N12 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000300 PRD_000300](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000300.svg) | PRD_000300 | Name: | N-acetyl-L-isoleucyl-L-alpha-glutamyl-N-[(1S)-2-carboxy-1-formylethyl]-L-prolinamide | Formula: | C22 H36 N4 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000301 PRD_000301](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000301.svg) | PRD_000301 | Name: | N-(2-oxoethyl)-L-isoleucyl-L-alpha-glutamyl-N-[(1R)-2-carboxy-1-formylethyl]-L-threoninamide | Formula: | C21 H36 N4 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000306 PRD_000306](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000306.svg) | PRD_000306 | Name: | KPFS-(CH2-NH)-LQF peptidomimetic inhibitor of PfPM1 | Formula: | C49 H77 N10 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000307 PRD_000307](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000307.svg) | PRD_000307 | Name: | N-acetyl-6-ammonio-L-norleucyl-L-glutaminyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-leucinamide | Formula: | C26 H52 Cl N9 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|